New oral pill regrows hair in six months, but the molecule isn't new

New oral pill regrows hair in six months, but the molecule isn't new

Veradermics has presented the results of its second clinical trial of an oral pill for hair loss: more than 1,000 men analyzed and, according to the company, visibly restored hair density within six months. If health authorities give the green light, it would be the first genuinely new oral drug for baldness in nearly three decades. The announcement has landed like a breath of fresh air in a country where half of all men keep a close eye on their receding hairline.

The fine print starts with the usual suspects. The dermatology community has been prescribing finasteride for decades, an inhibitor of the enzyme that converts testosterone into dihydrotestosterone, along with minoxidil, a vasodilator that is applied to the scalp or taken in low doses. Neither cures: they hold the ground. And finasteride has carried an uncomfortable fruta since the nineties for its effects on libido, which some patients describe as too high a price.

What sets this pill apart from the ones already out there

The novelty is not in the mechanism but in the packaging. Oral minoxidil has been used off-label for years, but at doses that caused blood spikes and rapid heartbeat. Veradermics' bet is a slow-release formulation, designed to keep levels stable and avoid those surges. That reading best fits the drug's profile and the molecule's track record.

That said, the data that have emerged come from the company itself and from a trial still in the publication stage. There is no regulatory approval, no price, and no guarantee that regulators will accept the package. The industry's history is full of spectacular phase-two trials that went nowhere.

The business is in the daily pill, not the cure

Here it helps to apply pharmaceutical industry logic. A treatment taken every day for decades is a recurring asset; a one-shot cure is bad business. That's why the model taking shape is not the miracle antibiotic but the statin or omeprazole: a perpetual pill, prescription renewals and a captive clientele.

The ten-year cost calculation, at a hypothetical market price, is the part no press release details. And without a price there is no way to compare it with generic finasteride, which costs pennies a day.

The side effects the leaflet doesn't shout about

The conversation about male sensual health remains a taboo with an expiration date. Some men quit finasteride because they preferred to keep their libido rather than their hair, and others take it without noticing anything. Individual variability is enormous, and the evidence on persistent sensual dysfunction remains scientifically disputed.

Oral minoxidil, for its part, is not harmless: it lowers blood pressure and can cause rapid heartbeat if the release profile isn't right. Hence the interest in the delayed-release formulation. Any such decision should go through a dermatologist, not a newspaper headline.

The announcement is real. The pill probably is too. What remains unclear is whether we're looking at a therapeutic breakthrough or a marketing operation with an old molecule in a new package.